Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression

Area of Science:

• Molecular biology
• Genetics
• Cancer research

Background:

• Non-small cell lung cancer (NSCLC) is frequently driven by mutations in the epidermal growth factor receptor (EGFR) gene.
• Targeting these specific oncogenic mutations is crucial for effective cancer therapy.

Purpose of the Study:

• To develop and evaluate a clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) system for selective elimination of mutant EGFR alleles.
• To assess the efficacy of this gene-editing strategy in reducing tumor growth and enhancing cancer cell death.

Main Methods:

• Utilized a CRISPR/Cas9 system with a specific single-guide RNA to target a common EGFR missense mutation (CTG > CGG).
• Delivered Cas9 and the guide RNA via adenovirus into lung cancer models.
• Evaluated gene editing specificity, cancer cell killing, and tumor reduction in a xenograft mouse model.

Main Results:

• Achieved highly accurate discrimination and disruption of the mutant EGFR allele over the wild-type allele.
• Demonstrated significantly enhanced cancer cell killing following CRISPR/Cas9 treatment.
• Observed a notable reduction in tumor size in the xenograft mouse model.

Conclusions:

• CRISPR/Cas9 gene editing provides a precise and effective strategy for targeting and eliminating oncogenic EGFR mutations in lung cancer.
• This approach holds promise as a novel therapeutic strategy for EGFR-mutated cancers and potentially other mutation-associated diseases.